Lactobacillus fermentum improved intestinal bacteria flora by reducing Clostridium perfringens

Ming Jer Shieh, Huey fang Shang, Fang Hsuean Liao, Jia Shi Zhu, Yi Wen Chien

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background & aim: Supplementation with probiotic Bifidobacteria or Lactobacilli or the combination of both, has been shown to maintain a healthy balance of bacterial flora in the intestinal lumen. A placebo-controlled, crossover, self-comparing clinical study evaluated the probiotic effects of Lactobacillus fermentum P.C.C. (ProBioPCC) on gastrointestinal bacterial flora. Methods: This 8-week trial comprised an initial lead-in week with no study intervention, a 3-week treatment phase (taking ProBio, 1 capsule/day), a 1-week washout phase, a 3-week control phase (taking placebo, 1 capsule/day), followed by a final week of washout. Thirty healthy adults (age: 25-43 years) having no gastrointestinal diseases were recruited into the study. Stool samples were collected once at each experimental week, and cultured for counting colonies of total anaerobic bacteria, Lactobacillus spp., Bifidobacterium spp., and Clostridium perfringens. Results: We found significantly increased colony counts of Lactobacillus spp. In stool samples after the treatment phase (p <0.05). Colony counts of probiotic Bifidobacterium spp. were significantly increased with the study intervention (p <0.05), while those of harmful C. perfringens were reduced (p <0.05). Ratios of Bifidobacterium spp. to total anaerobic bacteria and to C. perfringes were increased significantly (p <0.05). The bacteria colony counts and ratios returned toward baselines during and after the placebo control phase. In order to confirm the increase of intestinal probiotics was due to oral administration of ProBioPCC, we further demonstrated that L. fermentum P.C.C. strain was resistant against simulated gastric acid and bile in vitro. Conclusions: Our data indicate that ProBioPCC is effective in decreasing C. perfringens and increasing ratio of Bifidobacterium spp. to total anaerobic bacteria in healthy humans.

Original languageEnglish
Journale-SPEN
Volume6
Issue number2
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Lactobacillus fermentum
Clostridium perfringens
Probiotics
Bifidobacterium
Bacteria
Anaerobic Bacteria
Lactobacillus
Placebos
Capsules
Gastrointestinal Diseases
Gastric Acid
Bile
Oral Administration
Gastrointestinal Microbiome
Therapeutics

Keywords

  • Bifidobacterium spp.
  • Clostridium perfringens
  • Gastrointestinal bacterial flora
  • Lactobacillus fermentum PCC
  • Probiotic

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Lactobacillus fermentum improved intestinal bacteria flora by reducing Clostridium perfringens. / Shieh, Ming Jer; Shang, Huey fang; Liao, Fang Hsuean; Zhu, Jia Shi; Chien, Yi Wen.

In: e-SPEN, Vol. 6, No. 2, 04.2011.

Research output: Contribution to journalArticle

Shieh, Ming Jer ; Shang, Huey fang ; Liao, Fang Hsuean ; Zhu, Jia Shi ; Chien, Yi Wen. / Lactobacillus fermentum improved intestinal bacteria flora by reducing Clostridium perfringens. In: e-SPEN. 2011 ; Vol. 6, No. 2.
@article{4de13d6750a14ddebc7288e5a998f7bf,
title = "Lactobacillus fermentum improved intestinal bacteria flora by reducing Clostridium perfringens",
abstract = "Background & aim: Supplementation with probiotic Bifidobacteria or Lactobacilli or the combination of both, has been shown to maintain a healthy balance of bacterial flora in the intestinal lumen. A placebo-controlled, crossover, self-comparing clinical study evaluated the probiotic effects of Lactobacillus fermentum P.C.C. (ProBioPCC) on gastrointestinal bacterial flora. Methods: This 8-week trial comprised an initial lead-in week with no study intervention, a 3-week treatment phase (taking ProBio, 1 capsule/day), a 1-week washout phase, a 3-week control phase (taking placebo, 1 capsule/day), followed by a final week of washout. Thirty healthy adults (age: 25-43 years) having no gastrointestinal diseases were recruited into the study. Stool samples were collected once at each experimental week, and cultured for counting colonies of total anaerobic bacteria, Lactobacillus spp., Bifidobacterium spp., and Clostridium perfringens. Results: We found significantly increased colony counts of Lactobacillus spp. In stool samples after the treatment phase (p <0.05). Colony counts of probiotic Bifidobacterium spp. were significantly increased with the study intervention (p <0.05), while those of harmful C. perfringens were reduced (p <0.05). Ratios of Bifidobacterium spp. to total anaerobic bacteria and to C. perfringes were increased significantly (p <0.05). The bacteria colony counts and ratios returned toward baselines during and after the placebo control phase. In order to confirm the increase of intestinal probiotics was due to oral administration of ProBioPCC, we further demonstrated that L. fermentum P.C.C. strain was resistant against simulated gastric acid and bile in vitro. Conclusions: Our data indicate that ProBioPCC is effective in decreasing C. perfringens and increasing ratio of Bifidobacterium spp. to total anaerobic bacteria in healthy humans.",
keywords = "Bifidobacterium spp., Clostridium perfringens, Gastrointestinal bacterial flora, Lactobacillus fermentum PCC, Probiotic",
author = "Shieh, {Ming Jer} and Shang, {Huey fang} and Liao, {Fang Hsuean} and Zhu, {Jia Shi} and Chien, {Yi Wen}",
year = "2011",
month = "4",
doi = "10.1016/j.eclnm.2011.01.001",
language = "English",
volume = "6",
journal = "e-SPEN",
issn = "2212-8263",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Lactobacillus fermentum improved intestinal bacteria flora by reducing Clostridium perfringens

AU - Shieh, Ming Jer

AU - Shang, Huey fang

AU - Liao, Fang Hsuean

AU - Zhu, Jia Shi

AU - Chien, Yi Wen

PY - 2011/4

Y1 - 2011/4

N2 - Background & aim: Supplementation with probiotic Bifidobacteria or Lactobacilli or the combination of both, has been shown to maintain a healthy balance of bacterial flora in the intestinal lumen. A placebo-controlled, crossover, self-comparing clinical study evaluated the probiotic effects of Lactobacillus fermentum P.C.C. (ProBioPCC) on gastrointestinal bacterial flora. Methods: This 8-week trial comprised an initial lead-in week with no study intervention, a 3-week treatment phase (taking ProBio, 1 capsule/day), a 1-week washout phase, a 3-week control phase (taking placebo, 1 capsule/day), followed by a final week of washout. Thirty healthy adults (age: 25-43 years) having no gastrointestinal diseases were recruited into the study. Stool samples were collected once at each experimental week, and cultured for counting colonies of total anaerobic bacteria, Lactobacillus spp., Bifidobacterium spp., and Clostridium perfringens. Results: We found significantly increased colony counts of Lactobacillus spp. In stool samples after the treatment phase (p <0.05). Colony counts of probiotic Bifidobacterium spp. were significantly increased with the study intervention (p <0.05), while those of harmful C. perfringens were reduced (p <0.05). Ratios of Bifidobacterium spp. to total anaerobic bacteria and to C. perfringes were increased significantly (p <0.05). The bacteria colony counts and ratios returned toward baselines during and after the placebo control phase. In order to confirm the increase of intestinal probiotics was due to oral administration of ProBioPCC, we further demonstrated that L. fermentum P.C.C. strain was resistant against simulated gastric acid and bile in vitro. Conclusions: Our data indicate that ProBioPCC is effective in decreasing C. perfringens and increasing ratio of Bifidobacterium spp. to total anaerobic bacteria in healthy humans.

AB - Background & aim: Supplementation with probiotic Bifidobacteria or Lactobacilli or the combination of both, has been shown to maintain a healthy balance of bacterial flora in the intestinal lumen. A placebo-controlled, crossover, self-comparing clinical study evaluated the probiotic effects of Lactobacillus fermentum P.C.C. (ProBioPCC) on gastrointestinal bacterial flora. Methods: This 8-week trial comprised an initial lead-in week with no study intervention, a 3-week treatment phase (taking ProBio, 1 capsule/day), a 1-week washout phase, a 3-week control phase (taking placebo, 1 capsule/day), followed by a final week of washout. Thirty healthy adults (age: 25-43 years) having no gastrointestinal diseases were recruited into the study. Stool samples were collected once at each experimental week, and cultured for counting colonies of total anaerobic bacteria, Lactobacillus spp., Bifidobacterium spp., and Clostridium perfringens. Results: We found significantly increased colony counts of Lactobacillus spp. In stool samples after the treatment phase (p <0.05). Colony counts of probiotic Bifidobacterium spp. were significantly increased with the study intervention (p <0.05), while those of harmful C. perfringens were reduced (p <0.05). Ratios of Bifidobacterium spp. to total anaerobic bacteria and to C. perfringes were increased significantly (p <0.05). The bacteria colony counts and ratios returned toward baselines during and after the placebo control phase. In order to confirm the increase of intestinal probiotics was due to oral administration of ProBioPCC, we further demonstrated that L. fermentum P.C.C. strain was resistant against simulated gastric acid and bile in vitro. Conclusions: Our data indicate that ProBioPCC is effective in decreasing C. perfringens and increasing ratio of Bifidobacterium spp. to total anaerobic bacteria in healthy humans.

KW - Bifidobacterium spp.

KW - Clostridium perfringens

KW - Gastrointestinal bacterial flora

KW - Lactobacillus fermentum PCC

KW - Probiotic

UR - http://www.scopus.com/inward/record.url?scp=79952631598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952631598&partnerID=8YFLogxK

U2 - 10.1016/j.eclnm.2011.01.001

DO - 10.1016/j.eclnm.2011.01.001

M3 - Article

AN - SCOPUS:79952631598

VL - 6

JO - e-SPEN

JF - e-SPEN

SN - 2212-8263

IS - 2

ER -